Literature DB >> 20930595

Inhibition of atherosclerotic lesion development in the ApoE-/- mouse by a novel β-oxa polyunsaturated fatty acid.

Fatemeh Moheimani1, Lynette Moore, Judith V Ferrante, Neil Trout, Charles S Hii, Antonio Ferrante.   

Abstract

Recent findings that a novel polyunsaturated fatty acid, β-oxa 23:4n-6, inhibits adhesion molecule expression on vascular endothelial cells and leukocyte adhesion led us to examine its ability to inhibit the development of atherosclerosis in the apoE-deficient (apoE) mouse. The mice were kept on normal chow or a high-fat/high-cholesterol diet for various periods and treated with either vehicle or β-oxa 23:4n-6 by the intraperitoneal route. The hearts and aortae were isolated and lesion development at the aortic root was determined. Morphometric assessment revealed that lesion development was a function of compensatory aortic enlargement, suggesting that measurement of plaque size per se is the appropriate assessment of lesion size. Using this criterion, we found that atherosclerosis development was reduced in response to β-oxa 23:4n-6, plaque size by 74% and aortic cross-sectional area by 62%, under an optimized regime. The number of foam cells per unit tissue area in the lesions of β-oxa 23:4n-6-treated mice was significantly reduced by 37.5%. The blood levels of β-oxa23:4n-6 in these mice exceeded the concentrations previously found to inhibit adhesion molecule expression in cultured endothelial cells. These data show that β-oxa23:4n-6 protects against experimental atherosclerosis, most likely by reducing the number of infiltrating monocytes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20930595     DOI: 10.1097/FJC.0b013e3181f1d420

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  1 in total

1.  Effects of urotensin II and its specific receptor antagonist urantide on rat vascular smooth muscle cells.

Authors:  Juan Zhao; Shu-Feng Zhang; Yan Shi; Li-Qun Ren
Journal:  Bosn J Basic Med Sci       Date:  2013-05       Impact factor: 3.363

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.